Patents by Inventor Benjamin Wizel

Benjamin Wizel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IC31 nanoparticles
    Patent number: 9248180
    Abstract: The invention discloses pharmaceutical compositions in liquid form comprising a peptide with the amino acid sequence KLKL5KLK and an oligodeoxynucleotide with the nucleic acid sequence (dIdC)13 and wherein the peptide and the oligodeoxynucleotide are present as sterile-filterable nanoparticles in the composition, thereby forming a suspension, characterized in that the mean particle size of the solid particles is less than 1 ?m.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: February 2, 2016
    Assignee: Valneva Austria GmbH
    Inventors: Benjamin Wizel, Karin Riedl, Karen Lingnau, Ursula Schlosser, Jürgen Wruss, Robert Schlegl, Michael Weber, Christoph Reinisch, Ljubomir Paucz, Christoph Klade, Jee Loon Look, Christian Ruiz, Robert Seid
  • MUTANT FRAGMENTS OF OspA AND METHODS AND USES RELATING THERETO
    Publication number: 20150250865
    Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
    Type: Application
    Filed: February 17, 2015
    Publication date: September 10, 2015
    Applicant: Valneva Austria GmbH
    Inventors: Pär Comstedt, Markus Hanner, Urban Lundberg, Andreas Meinke, Wolfgang Schüler, Benjamin Wizel
  • MUTANT FRAGMENTS OF OspA AND METHODS AND USES RELATING THERETO
    Publication number: 20150232517
    Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
    Type: Application
    Filed: July 8, 2013
    Publication date: August 20, 2015
    Inventors: Pär Comstedt, Urban Lundberg, Andreas Meinke, Markus Hanner, Wolfgang Schüler, Benjamin Wizel, Christoph Reinisch, Brigitte Grohmann, Robert Schlegl
  • IC31 NANOPARTICLES
    Publication number: 20150216967
    Abstract: The invention discloses pharmaceutical compositions in liquid form comprising a peptide with the amino acid sequence KLKL5KLK and an oligodeoxynucleotide with the nucleic acid sequence (dIdC)13 and wherein the peptide and the oligodeoxynucleotide are present as sterile-filterable nanoparticles in the composition, thereby forming a suspension, characterized in that the mean particle size of the solid particles is less than 1 ?m.
    Type: Application
    Filed: April 22, 2014
    Publication date: August 6, 2015
    Applicant: Valneva Austria GmbH
    Inventors: Benjamin Wizel, Karin Riedl, Karen Lingnau, Ursula Schlosser, Jürgen Wruss, Robert Schlegl, Michael Weber, Christoph Reinisch, Ljubomir Paucz, Christoph Klade, Jee Loon Look, Christian Ruiz, Robert Seid
  • Mutant fragments of OspA and methods and uses relating thereto
    Patent number: 8986704
    Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: March 24, 2015
    Assignee: Valneva Austria GmbH
    Inventors: Pär Comstedt, Markus Hanner, Urban Lundberg, Andreas Meinke, Wolfgang Schueler, Benjamin Wizel
  • 1C31 nanoparticles
    Patent number: 8765148
    Abstract: The invention discloses pharmaceutical compositions in liquid form comprising a peptide with the amino acid sequence KLKL5KLK and an oligodeoxynucleotide with the nucleic acid sequence (dIdC)13 and wherein the peptide and the oligodeoxynucleotide are present as sterile-filterable nanoparticles in the composition, thereby forming a suspension, characterized in that the mean particle size of the solid particles is less than 1 ?m.
    Type: Grant
    Filed: February 21, 2011
    Date of Patent: July 1, 2014
    Assignee: Valneva Austria GmbH
    Inventors: Benjamin Wizel, Karin Riedl, Karen Lingnau, Ursula Schlosser, Jürgen Wruss, Robert Schlegl, Michael Weber, Christoph Reinisch, Ljubomir Paucz, Christoph Klade, Jee Loon Look, Christian Ruiz, Robert Seid
  • MUTANT FRAGMENTS OF OspA AND METHODS AND USES RELATING THERETO
    Publication number: 20140010835
    Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
    Type: Application
    Filed: March 14, 2013
    Publication date: January 9, 2014
    Inventors: Pär Comstedt, Markus Hanner, Urban Lundberg, Andreas Meinke, Wolfgang Schueler, Benjamin Wizel
  • IC31 NANOPARTICLES
    Publication number: 20120308618
    Abstract: The invention discloses pharmaceutical compositions in liquid form comprising a peptide with the amino acid sequence KLKL5KLK and an oligodeoxynucleotide with the nucleic acid sequence (dIdC)13 and wherein the peptide and the oligodeoxynucleotide are present as sterile-filterable nanoparticles in the composition, thereby forming a suspension, characterized in that the mean particle size of the solid particles is less than 1 ?m.
    Type: Application
    Filed: February 21, 2011
    Publication date: December 6, 2012
    Applicant: Intercell AG
    Inventors: Benjamin Wizel, Karin Riedl, Karen Lingnau, Ursula Schlosser, Jürgen Wruss, Robert Schlegl, Michael Weber, Christoph Reinisch, Ljubomir Paucz, Christoph Klade, Jee Loon Look, Christian Ruiz, Robert Seid